IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson’s Disease

Gothenburg, Sweden, December 23, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company focused on discovering and developing new treatments for Parkinson’s disease, has received regulatory and ethical approvals for a Phase Ib study of IRL757 to assess safety, tolerability, and signal finding in patients with Parkinson’s disease who experience apathy. The study will be conducted at 16 sites across four European countries and is fully funded by IRLAB’s development collaborator, the McQuade Center for Strategic Research and Development, LLC (MSRD) –an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd.

The European Patent Office intends to grant a new patent for IRLAB’s mesdopetam.

IRLAB participates in Redeye Technology & Life Science Day on December 3, 2025